At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Routine Rectal Indomethacin Given Before Procedure Reduced Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial
In Brief
A clinical study evaluating Pre-ERCP rectal Indomethacin and Post-operational Rectal Indomethacin for Post-ERCP Acute Pancreatitis. Completed, enrolled 2,600 participants across 6 sites.
Detailed Summary
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. However, the risk factors of PEP is not fully clear. Rectal indomethacin before ERCP for all patients, not just for selected high-risk patients, may preventing PEP maximum. The purpose of this study is to determine whether routine using of rectal indomethacin is more effective than the conditional strategy.
Study Details
Timeline
Interventions
Rectal Indomethacin was administrated within 30min before ERCP in all patients.
Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.